Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 37.36 [1]. Core Insights - The company achieved a revenue of CNY 3.001 billion in 2025, representing a year-on-year increase of 16.7%, and a net profit attributable to shareholders of CNY 318 million, up 39.0%, which aligns with expectations [6]. - The company continues to show strong fundamentals, with same-store sales growth of 6.9% and a high dividend payout ratio, with a year-end dividend of HKD 0.72 per share [6]. - The company is positioned as a leader in the beauty and health chain service sector, benefiting from a "dual beauty + dual healthcare" strategy, and is expected to leverage high-end consumption recovery trends for mid-term growth [6][10]. Financial Performance - Revenue projections for 2026 and 2027 have been revised upwards to CNY 39.15 billion and CNY 43.15 billion, respectively, reflecting increases of 18.6% and 21.5% [10]. - The company’s gross margin improved to 49.1% in 2025, up 2.8 percentage points year-on-year, driven by cost optimization and acquisitions [8]. - Operating cash flow for 2025 reached CNY 1.0 billion, marking a 25.4% increase year-on-year, demonstrating strong cash generation capabilities [9]. Business Segments - The beauty and wellness services segment generated revenue of CNY 1.658 billion in 2025, up 14.9%, with direct and franchise income growing by 15.8% and 5.9%, respectively [7]. - The medical beauty services segment reported revenue of CNY 1.017 billion, a year-on-year increase of 9.6%, with significant growth in customer traffic and average spending [7]. - The sub-health medical services segment saw remarkable growth, achieving revenue of CNY 326 million, up 62.2%, contributing to 10.9% of total revenue [7]. Valuation Metrics - The company’s projected PE ratio for 2026 is set at 19 times, reflecting its leading position in the beauty chain sector and expected growth from both organic and acquisition strategies [10]. - The report indicates a projected EPS of CNY 1.76 for 2026, with a continued focus on enhancing profitability through operational efficiencies [10].

Core Viewpoint - The company is focusing on a dual-brand strategy through the acquisition and integration of Narier and Siyuanli, aiming to enhance operational efficiency and establish a strong presence in high-end commercial areas, with a significantly lower customer acquisition cost compared to industry averages [1] Event Summary - On October 15, the company announced a plan to acquire 100% equity of Siyuanli, the third-largest beauty service brand in China, for a consideration of 1.25 billion RMB [1] - On November 4, the company announced a commitment to distribute dividends of no less than 50% of the net profit attributable to shareholders for the next three complete fiscal years, barring any special circumstances [1] Business Integration - The acquisition of Siyuanli will enhance the company's mid-to-high-end market positioning, with Siyuanli projected to generate revenue of 849 million RMB in 2024 and operate 163 beauty service stores and 19 medical beauty clinics across 48 cities by mid-2025 [1] - The acquisition will consolidate the top three beauty service brands in the country, capturing 42% of high-end commercial properties in first and second-tier cities, thereby strengthening overall competitiveness and leveraging synergies [1] - Siyuanli's net profit is expected to reach 81 million RMB in 2024, with potential for profit margin improvement similar to Narier's post-acquisition performance [1] Financial Metrics - The acquisition price of 1.25 billion RMB corresponds to a TTM P/E ratio of approximately 17, which is lower than the valuation of listed companies, and the payment will be made through a combination of cash and share issuance [1] - The company has repurchased 605,500 shares recently, with plans to maintain a dividend payout ratio of at least 50% over the next three years, enhancing long-term return attractiveness [2] Profit Forecast - The company expects to optimize its business model further during the expansion process, with updated net profit projections for 2025-2027 at 372 million, 409 million, and 486 million RMB, corresponding to P/E ratios of 18X, 17X, and 14X respectively, maintaining a "buy" rating [2]

Core Viewpoint - The acquisition of Siyanli by Meili Tianyuan Medical Health (02373) is expected to solidify its position in the mid-to-high-end beauty care services market, with potential for further optimization in its business model through both organic and external growth strategies [1][2] Group 1: Acquisition Details - The company announced on October 15 that it will acquire 100% equity of Siyanli, the third-largest beauty service brand in China, for a consideration of 1.25 billion RMB [1] - Siyanli operates 163 beauty service stores and 19 medical beauty clinics across 48 cities in China, with approximately 60,000 active members [2] - The acquisition is expected to enhance the company's overall competitiveness and leverage synergies, as it will consolidate the top three beauty service brands in the country [2] Group 2: Financial Projections - The company updated its net profit forecasts for 2025-2027 to 372 million, 409 million, and 486 million RMB, respectively, with corresponding P/E ratios of 18X, 17X, and 14X [1] - Siyanli is projected to achieve a net profit of 81 million RMB in 2024, with expectations of improving its profit margin from 6.5% in 2023 to 10.4% by the first half of 2025 after integration [2] - The acquisition price corresponds to a TTM P/E valuation of approximately 17 times, which is lower than the valuation of the listed company [2] Group 3: Shareholder Returns - The company plans to maintain a dividend payout of no less than 50% of the net profit attributable to shareholders for the next three complete financial years [1][2] - The company has been actively repurchasing shares to support its market price, having repurchased 605,500 shares out of an authorized 23.58 million shares [2]